HMGB1-antagonism exerted by glycyrrhizin could be fruitful against COVID-19.
Acta Biomed
; 92(S6): e2021455, 2021 10 01.
Article
in English
| MEDLINE | ID: covidwho-1503761
ABSTRACT
The COVID-19 pandemic era is causing a relevant issue for the health. There is no specific drug able to antagonize the SARS-CoV-2 infection. As a consequence, there is growing interest about potential molecules able to contrast infection. In this regard, HMGB, an alarmin, may play a relevant role in pathogenic mechanisms induced by SARS-CoV-2. As HMGB1 is antagonized by glycyrrhizin, this substance could be potentially useful as ancillary treatment in COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
HMGB1 Protein
/
COVID-19
Limits:
Humans
Language:
English
Journal:
Acta Biomed
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
Abm.v92iS6.12111
Similar
MEDLINE
...
LILACS
LIS